Introduction
Nowadays, approximately 70% of the children diagnosed with acute lymphoblastic leukemia (ALL) and treated using combination chemotherapy achieve and remain in continuous complete remission. For a minority of patients with ALL, however, the prognosis is far less promising. Infants (ie children p12 months of age) form the most striking example of a subgroup of ALL patients who have failed to benefit from the greatly improved treatment regimens developed over the last few decades. The prognosis for infants with ALL is still very poor, with an event-free survival (EFS) of approximately 35%. 1 Treatment failure in infant ALL patients is associated with cellular drug resistance. Pieters et al 2 demonstrated that leukemic cells from infants with ALL are in vitro significantly more resistant to chemotherapeutic drugs, especially to prednisone and L-asparaginase, compared to cells from older children with ALL. One exception, however, is Ara-C to which infant ALL cells are highly sensitive. 2 Multidrug resistance (MDR) is described as (cross)resistance to structurally unrelated cytotoxic drugs, which severely limits the effectiveness of the chemotherapeutic treatment of the patient. Since leukemic cells from infants with ALL are in vitro resistant to multiple chemotherapeutic drugs, infant ALL patients can legitimately be classified as multidrug resistant. MDR has been associated with decreased cellular drug retention as a result of increased drug efflux mediated by specialized ATP-dependent transmembrane transporter proteins. Several MDR-related drug efflux proteins have been characterized, most of which appear to be members of the ATP-binding cassette (ABC) transporter superfamily. The most extensively studied MDR protein is the permeability-glycoprotein (P-gp) encoded by the MDR1 gene. P-gp has been described to have a broad substrate specificity, decreasing the intracellular retention of, among others, anthracyclins (eg daunorubicin, doxorubicin), anthracenes (eg mitoxantrone), vinca alkaloids (eg vincristine, vinblastine) and epipodophyllotoxins (etoposide and teniposide). 3 Other identified MDR proteins are the MDR-related protein 1 (MRP1), 4 lung resistance-related protein/major vault protein (LRP/MVP) 5 and the recently discovered breast cancer resistance protein (BCRP). 6, 7 MRP1 is a member of the MRP family of ABC transporters, of which to date eight members have been identified. So far, MRP1 is the only MRP family member associated with clinical MDR. Although MRP1 shares only 15% homology with P-gp, the phenotype associated with MRP1 overexpression results in an MDR phenotype comparable to that of P-gp-overexpressing cells. 8 BCRP is evolutionarily distinct from the other ABC transporters, lying on a separate limb of the phylogenetic tree, 9 and its gene encodes a half-transporter that dimerizes to form an active transporter. 10 This may suggest a separate role for BCRP in clinical drug resistance. To date, accepted substrates for BCRP include camptothecins, mitoxantrone and related molecules 11 and methotrexate. 12 LRP was identified as the major vault protein, 13 an important component of well-conserved cellular organelles called vaults, which are upregulated in multidrug-resistant cancer cell lines.
14 Unlike P-gp, MRP1 and BCRP, LRP/MVP is not a member of the ABC transporter family. It is thought that LRP/MVP decreases the effectiveness of cytotoxic drugs, either by regulating nucleuscytoplasmatic transport of cytotoxic drugs away from the nucleus and/or by involvement in sequestration of cytotoxic drugs in exocytotic vesicles. 13 LRP/MVP has been reported to be involved in resistance to vincristine, doxorubicin and etoposide. 15 The exact clinical value of the above MDR proteins in childhood ALL is not clear, and existing data are conflicting. 16 To date, however, no data exist on the possible role these MDR efflux proteins might play in the observed drug resistance in infant ALL patients. Therefore, we measured and compared the expression levels of MDR1, MRP1, LRP/MVP and BCRP using real-time quantitative RT-PCR (Taqman) analysis, in infants and non-infants diagnosed with ALL. In addition, the obtained mRNA expression levels of the MDR genes were correlated to cytotoxicity to several important chemotherapeutic drugs used in the treatment of childhood ALL.
Patients, materials and methods

Patient samples
Bone marrow and/or peripheral blood samples of 13 untreated infants (p12 months of age) initially diagnosed with ALL were collected from the Sophia Children's Hospital/Erasmus MC and other hospitals participating in the INTERFANT-99 treatment protocol. Samples of 13 initially diagnosed ALL patients older than 12 months of age were obtained from the German COALL study group (Professor Dr GE Janka-Schaub, Hamburg, Germany). The median age in the infant and non-infant group was 0.5 and 6.0 years, respectively. The immunophenotype of the infants was predominantly Pro-B and Pre-B, whereas most noninfant ALL patients had a common-ALL immunophenotype. In the infant group, 77% of the patients had a rearrangement of the MLL gene on chromosome 11q23. In contrast, all the non-infant ALL patients had germ-line MLL genes.
Within 24 h after sampling, mononuclear cells were isolated by density gradient centrifugation using Lymphoprep (density 1.077 g/ml; Nycomed Pharma, Oslo, Norway), centrifuged at 480 g for 15 min at room temperature. The collected mononuclear cells were washed twice and kept in culture medium consisting of RPMI 1640 medium (Dutch modification without L-glutamine; Gibco BRL, Life Technologies), 20% fetal calf serum (FCS; Integro, Zaandam, The Netherlands), 2 mM L-glutamine (Gibco BRL, Life Technologies, Breda, The Netherlands), 5 mg/ml insulin, 5 mg/ml transferrin, 5 ng/ml sodium selenite (ITS media supplement; Sigma, St Louis, MO, USA), 100 IU/ml penicillin, 100 mg/ml streptomycin, 0.125 mg/ml fungizone (Gibco BRL, Life Technologies) and 0.2 mg/ml gentamycin (Gibco BRL, Life Technologies). Contaminating nonleukemic cells were removed using immunomagnetic beads (Dynal ASA, Oslo, Norway). All samples contained X90% leukemic cells, determined morphologically on May-Grü nwald-Giemsa (Merck, Darmstadt, Germany)-stained cytospins.
RNA extraction and cDNA synthesis
Total cellular RNA was extracted from a minimum of 5 Â 10 6 cells using TRIzol reagent (Gibco BRL, Life Technologies) according to the manufacturer's protocol, except for minor modifications. An additional phenol-chloroform extraction was performed and the isopropanol precipitation at À201C was facilitated by adding 1 ml (20 mg/ml) glycogen (Roche, Almere, The Netherlands). After precipitation with isopropanol, RNA pellets were dissolved in 20 ml RNAse-free TE-buffer (10 mM Tris-HCl, 1 mM EDTA, pH ¼ 8.0). The RNA was quantified spectrophotometrically. Following a denaturation step of 5 min at 701C, 1 mg of RNA was reverse transcribed to single-stranded cDNA using a mix of random hexamers (2.5 mM) and oligo dT primers (20 nM). The RT reaction was performed in a total volume of 25 ml containing 0. 
Quantitative real-time PCR (Taqman technology)
The mRNA expression levels of MDR1, MRP1, LRP/MVP and BCRP and the endogenous housekeeping gene GAPDH as a reference were quantified using real-time PCR analysis (Taqman) essentially as described recently. 17 On an ABI Prism 7700 sequence detection system (PE Applied Biosystems), specific PCR products were amplified and detected using dual-fluorescent nonextendable probes labeled with 6-carboxyfluorescein (FAM) and 6-carboxytetramethylrhodamine (TAM-RA) at the 5 0 -end and 3 0 -end, respectively. Primers and probe combinations, reported previously, 17 were designed using OLIGO 6.0 primer analysis software (Medprobe, Olso, Norway). All PCRs showed comparable efficiencies of EX95%, and were performed in duplicate in a reaction volume of 50 ml containing 1 Â Taqman buffer A (PE Applied Biosystems), 4 mM MgCl 2 , 200 mM of each dNTP (Amersham Pharmacia Biotech), 300 nM forward and reverse primer, 200 nM probe, 1.25 U AmpliTaq Gold DNA polymerase (Applied Biosystems) and 40 ng of cDNA from each patient as a template. Samples were heated for 10 min at 951C and amplified for 40 cycles of 15 s at 951C and 60 s at 601C. A serial dilution of cDNA derived from a cell line RNApool (CEM, K562, and two EBV-transformed lymphoblastoid B-cell lines) was amplified in parallel as a control to verify amplification efficiency within each experiment. For each patient, the relative mRNA expression levels of MDR1, MRP1, LRP/MVP and BCRP were calculated using the comparative cycle time (C t ) method. 18 Briefly, the target PCR C t values, that is, the cycle number at which emitted fluorescence exceeds 10 Â the standard deviation of base-line emissions as measured from cycles 3-15, are normalized to the GAPDH PCR C t value by subtracting the GAPDH C t value from the target PCR C t value. The relative mRNA expression level to GAPDH for each target PCR can be calculated using the following equation:
In vitro drug cytotoxicity assay (MTT assay)
In vitro drug cytotoxicity was determined using the MTT assay as described by Pieters et al. 19 Briefly, 100 ml aliquots of cell suspension (1.6 Â 10 5 cells) were cultured in roundbottomed 96-well microtiter plates in the presence of six different concentrations of each drug in duplicate. The drugs tested were: prednisolone (PRED, Bufa, Uitgeest, The Netherlands), vincristine (VCR, Teva Pharma, Mijdrecht, The Netherlands), daunorubicin (DNR, Rhô ne-Poulenc-Rorer, Amstelveen, The Netherlands) and Ara-C (Cytosar, Pharmacia & Upjohn BV, Woerden, The Netherlands). The range of end concentrations and the dilution factors were: PRED (0.0076-250 mg/ml, eight-fold), VCR (0.049-50 mg/ml, fourfold), DNR (0.0019-2 mg/ml, four-fold) and Ara-C (0097-10 mg/ml, four-fold). Control cells were cultured in eight wells in the absence of drugs. Four wells containing 100 ml culture medium were used as blanks. After incubating the plates for 4 days at 371C in humidified air containing 5% CO 2 , 10ml of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazoliumbromide (MTT, 5 mg/ml; Sigma Aldrich, Zwijndrecht, The Netherlands) was added and the plates were incubated for an additional 6 h under the same conditions. During this final 6-h incubation, the yellow MTT tetrazolium salt is reduced to purpleblue formazan crystals by viable cells only. The formazan crystals were dissolved by adding 100 ml of acidified isopropanol (0.04 N HCl-isopropyl alcohol) and the optical density (OD), which is linearly related to the number of viable cells, 20 was measured spectrophotometrically at 562 nm. After subtraction of the blank values, the leukemic cell survival (LCS) was calculated by the equation:
LCS ¼ ðOD Day4 treated well=mean OD Day 4 control wellsÞ
Â100%
Drug sensitivity was assessed by the LC 50 , the drug concentration lethal to 50% of the cells. Evaluable assay results were obtained when a minimum of 70% leukemic cells were present in the control wells after 4 days of incubation and when the control optical density (OD) was X0.050
.
To determine Ara-C cytotoxicity in the absence and presence of the specific BCRP inhibitor Ko143, 21 leukemic cells from patients were preincubated with 200 nM Ko143 or with an equal volume of PBS for 1 h at 371C in humidified air containing 5% CO 2 . Without washing the cells or removing the inhibitor from the culture medium, Ara-C cytotoxicity was determined using the MTT assay as described above.
Cytotoxicity assays in the Mef38 and Mef3.8/T6400 cell lines
Both cell lines were maintained in DMEM supplemented with 10% FCS (HyClone), 10 mM HEPES, penicillin and streptomycin. MEF3.8 cells are adherent mouse embryo fibroblasts, which are nullizygous for P-gp and Mrp1. 22 The MEF3.8/T6400 subline was obtained by selection for resistance to topotecan, and expresses high levels of wildtype Bcrp1. 22, 23 The subline was routinely maintained under continuous selection with 6.4 mM topotecan, but this was reduced to 0.64 mM 2 days prior to use of the cells in the cytotoxicity assay.
Subconfluent cells were seeded in 96-well plates at a density of 500 cells/well in a volume of 100 ml. After allowing attachment of the cells for 4 h, the cells were exposed to a concentration series of Ara-C or mitoxantrone, in the presence or absence of 200 nM of the specific Bcrp1 inhibitor Ko143. After 4-5 days, while cells were still subconfluent in the untreated wells, the wells were stained with 1:4000 Sybr Green I (Molecular Probes, Eugene, OR, USA) nucleic acid stain, diluted in a hypotonic lysis buffer (10 mM Tris, pH 8.0, 2.5 mM EDTA, 0.1% Triton X-100) using 200 ml/well, and allowing equilibration for 24 h at 41C in the dark. Relative cell proliferation was quantified by measuring Sybr Green I fluorescence using a plate reader (Cytofluor 4000; PerSpective Biosystems, Framingham, MA, USA) with 485 nm excitation and 530 nm emission filters. Cytotoxicity of the drugs was expressed as the IC 50 value, that is, the concentration of drugs that inhibits 50% of the growth of the cells.
Results
Using real-time quantitative RT-PCR (Taqman technology), the mRNA expression levels of MDR1, MRP1, LRP/MVP and BCRP were measured in leukemic cells from infants (n ¼ 13) and older children (n ¼ 13) with newly diagnosed ALL. Infants expressed significantly less BCRP mRNA (P ¼ 0.009) compared to older children with ALL. The difference in the median relative BCRP mRNA expression between the infant and non-infant group was 2.4-fold. No significant differences in the mRNA expression of MDR1, MRP1 and LRP/MVP were found, although a trend toward decreased MRP1 mRNA expression in infants was observed (Figure 1 ).
The obtained mRNA levels of the MDR genes were correlated to the cytotoxicity of several important chemotherapeutic drugs used in the treatment of childhood ALL, like prednisone, vincristine, daunorubicin and Ara-C. No positive correlation was observed between the mRNA expression of MDR1, MRP1, BCRP or LRP/MVP and the cytotoxicity of the drugs tested, except for BCRP and Ara-C. BCRP mRNA expression positively correlated with the LC 50 values of Ara-C (R s ¼ 0.53, P ¼ 0.012) (Figure 2 ). These findings suggest that Ara-C might be a substrate for BCRP, and that Ara-C sensitivity in infant ALL may be explained by a decreased efflux of Ara-C out of these cells, mediated by BCRP. To test this hypothesis, Ara-C cytotoxicity in the leukemic cells from two Ara-C-resistant and two Ara-Csensitive ALL patients was determined both in the absence and presence of 200 nM of the specific BCRP inhibitor Ko143. Inhibition of BCRP by 200 nM of Ko143, however, had no effect on Ara-C cytotoxicity (Figure 3 ). In addition, cytotoxicity to Ara-C and mitoxantrone was determined in cells from the Mdr1a/b À/À , Mrp1 À/À mouse embryo fibroblast cell line MEF3.8 and the Bcrp1 (the mouse homologue of human BCRP)-overexpressing subline MEF3.8/T6400, both in the presence and absence of 200 nM of Ko143 (Table 1) . Although the Bcrp1-overexpressing subline MEF3.8/T6400, derived by selection for topotecan resistance, appeared to be significantly more resistant to Ara-C compared to the parental MEF3.8 cell line (Po0.05), inhibition of Bcrp1 by Ko143 did not alter Ara-C cytotoxicity. Mitoxantrone, a known substrate for BCRP, served as a positive control in these experiments. Ko143 markedly sensitized the MEF3.8/T6400 cells 68-fold to mitoxantrone (Po0.001) ( Table 1) .
Discussion
MDR is attributed to the overexpression of certain efflux proteins that are capable of trafficking chemotherapeutic drugs out of the cell, like P-gp, MRP1 and BCRP, or away from the nucleus by LRP/MVP. The exact clinical value of these MDR proteins in childhood ALL, however, is not clear, and existing data are conflicting. 16 Increased levels of P-gp expression, both at the protein 24, 25 and mRNA level, 26 as well as increased P-gp function 27, 28 have been shown to be significant unfavorable prognostic factors for clinical outcome in childhood ALL. Other studies, however, contradict the finding that P-gp expression is of clinical value. [29] [30] [31] Data on the prognostic significance of the other MDR proteins in childhood ALL are scarce. One study on a group of Indian ALL patients, most of whom were children, reported significantly higher MRP1 mRNA expression at relapse than at presentation or remission. 32 However, this finding has not been confirmed by others, 33, 34 and MRP1 measured at the protein level appeared to have no prognostic importance 30 in another study. LRP/MVP mRNA expression has been reported not to be of prognostic value in newly diagnosed childhood ALL. 33 Furthermore, no differences in LRP/MVP protein expression have been reported between initial and relapse ALL samples, 30 only in multiple relapse samples LRP/MVP expression was found to be significantly increased. Evenso, it has been suggested that children with initial ALL and no detectable LRP/ MVP expression experience significantly longer relapse-free intervals compared to patients with LRP expression. 35 Additional studies from our laboratory on a group of 146 uniformly treated children with ALL showed that neither P-gp, MRP1 nor LRP/MVP expression, measured at initial diagnosis, correlated with clinical outcome after combination chemotherapy (unpublished data). To date, only a single study on BCRP expression in childhood ALL has been reported, in which BCRP mRNA was measured in 47 initial and 20 relapsed ALL samples. No differences between initial and relapsed ALL were observed, and BCRP mRNA expression did not seem to have any prognostic significance. 36 There are no published data either on the role the MDR proteins play in infant ALL or on possible differences in the expression of the MDR genes between infants and older children Figure 2 Relation between Ara-C cytotoxicity and BCRP mRNA expression in pediatric ALL. The correlation between the Ara-C cytotoxicity (LC 50 in mg/ml) and the relative expression of BCRP mRNA was calculated using the Spearman's rank correlation test. Open circles (J) indicate infants with ALL and closed circles (K) non-infant ALL patients. Ara-C cytotoxicity determined in two Ara-C-resistant and two Ara-C-sensitive patients with ALL in the absence and presence of 200 nM of the specific BCRP inhibitor Ko143. with ALL. However, since infants with ALL are more resistant to chemotherapeutic drugs than older children, 2 such data might contribute to our understanding of the mechanisms underlying drug resistance in infant ALL, which to date remain unknown. Hence, we measured the mRNA levels of MDR1, MRP1, LRP/ MVP and BCRP infants and non-infant ALL samples using realtime quantitative RT-PCR. The only significant difference observed between both groups was that infants expressed 2.4-fold less BCRP mRNA. Furthermore, the only significant correlation found between the mRNA expression of the four MDR proteins and the cytotoxicity of several important chemotherapeutic drugs was between BCRP and Ara-C. The observed relationship indicated that patients with increased mRNA levels of BCRP are likely to be more resistant to Ara-C compared to children with lower BCRP mRNA levels, suggesting that Ara-C might be a substrate for BCRP. Nevertheless, culturing leukemic cells form ALL patients in the presence of Ko143, a specific BCRP inhibitor, 21 did not sensitize the leukemic cells to Ara-C. That Ara-C was not a substrate for BCRP was confirmed by cell line studies. Given the profound similarities between human BCRP and its mouse cognate Bcrp1, 23 the P-gp-and Mrp1-deficient mouse embryo fibroblast cell line MEF3.8 and its Bcrp1-overexpressing subline MEF3.8/ T6400
22 constitute a sound model for studying BCRP. Inhibition of Bcrp1 in these cell lines did not modulate Ara-C cytotoxicity, whereas both cell lines were markedly sensitized to mitoxantrone, a known substrate for BCRP. 11 In the MEF3.8/T6400 subline, 200 nM of Ko143 completely reversed the high level of resistance to mitoxantrone, demonstrating that culturing cells in the presence of this concentration of Ko143 indeed thoroughly inhibits Bcrp1 function.
Taken together our data suggest that, despite the observed correlation between BCRP mRNA expression and Ara-C resistance, Ara-C is not a substrate for BCRP. Moreover, since leukemic cells from infants are more resistant to chemotherapeutic drugs, especially to prednisone, compared to older children with ALL, 2 but do not show increased expression of MDR genes tested, we conclude that MDR proteins are unlikely to play a significant role in clinical drug resistance in infants with ALL.
